This association may reflect the use of angiotensin-converting enzyme inhibitors/angiotensin II antagonists (ACEI/ARA) and/or spironolactone, or perhaps the presence of comorbidities already included in our analysis, such as heart or renal failure. This evidence concerns the gene ACE and acute kidney injury.